2026 Taiwan Pharmaceutical Alliance

State of The Art Technology

Cost-Effective Service

CMO/CDMO/CRO/CRDMO

In/Out Licensing

API/FDF/Biosimilar

Industrial Development Administration
MOEA

Medical and Pharmaceutical Industry
Technology and Development Center

Contents

About TPA 02

TPA Members 04

Members Services List 06

Bionovax Corp. 10

Cenra Pharma 11

SyntroMed 12

Krisan Biotech Co., Ltd. 13

Mithra Biotechnology Inc. 14

Orient EuroPharm Co., Ltd. 15

Pei Li Pharmaceutical Industrial Co.,Ltd. 16

Prince Pharmaceutical Co., Ltd. 17

Panion & BF Biotech Inc. 18

Savior Lifetec Corporation 19

Sinphar Pharmaceutical Co. Ltd. 20

Standard Chem & Pharm Co., Ltd. 21

Sunny Pharmtech Inc. 22

Swiss Pharmaceutical Co., Ltd. 23

Synmosa Biopharma Corporation 24

Syn-Tech Chem.& Pharm. Co., Ltd. 25

Ta Fong Pharmaceutical Co., Ltd. 26

Taiwan Tasheh Biotech Co.,Ltd. 27

Taiwan Tasheh Biotech Co.,Ltd. 28

UBI Pharma Inc. 29

Yuan Chou Chemical & Pharmaceutical Co., Ltd. 30

Yung Shin Pharm. Ind. Co., Ltd. 31

Yung Zip Chemical Ind. Co., Ltd. 32

Your BEST Partner in Aisa

Contact TPA

www.tpatw.org.tw

BDD@pitdc.org.tw

+886-2-6625-1166

TPA Overview

The **Taiwan Pharmaceutical Alliance (TPA)** is a pivot hub connecting Taiwan's pharmaceutical industry. Established by the Medical and Pharmaceutical Industry Technology and Development Center (PITDC) with support of Ministry of Economic Affairs, TPA fosters collaboration, drives innovation, and links Taiwan's capabilities to global pharmaceutical markets.

Vision

TPA aims to build a global pharmaceutical network, foster international partnerships, and provide a high-quality, reliable supply chain, creating mutually beneficial opportunities worldwide.

Membership & Global Reach

TPA comprises more than 23 member companies, each contributing expertise across therapeutic areas. The Alliance maintains a strong presence in the United States, Europe, Japan, ASEAN, and MENA markets.

Total Solution Services

TPA provides **End-to-End services** from drug R&D and clinical trials to finished product manufacturing. Members support flexible collaborations and advanced technologies, including hot-melt extrusion, nano-grinding, continuous manufacturing, and specialized in unique dosage forms such as LAIs, OROS, and pre-filled syringes (PFS) etc.

Global Expertise & Compliance

TPA members rigorously **adhere to PIC/S GMP standards and have successfully undergone inspections by the US, JP, EU, TGA, and relevant authorities in the MENA region.** These certifications affirm the Alliance's capability to maintain a reliable and high-quality pharmaceutical supply chain for international partners.

Diverse Product Portfolio

TPA offers a wide range of products, including ADCs, PDCs, High-Potency drugs, APIs, 505(b)(2) medicines, niche generics, and biosimilars. Finished dosage forms cover oral solids and liquids, semi-solids, injectables, ophthalmic, aerosol, nasal sprays, transdermal patches, and topicals.

One-Stop Services

- CDMO, CMO, CRDMO, CRO
- In/Out Licensing
- Regulatory & IP Consultation

Commercialised Products

- APIs, Rx, OCTs, 505 (b)(2), Medical Supplies
- Generics, Hormone, High Potency
- ADC, PDC

Special Dosage Forms

- Prefilled Syringe
- Aerosol
- Long-Acting Injectables (LAIs)
- Osmotic-Controlled Release Delivery System (OROS)
- Soft Capsules

Technology Features

- Hotmelt-Extrusions (HME)
- Nanotechnology
- Spray Dry
- Continuous Manufacturing

TPA Members

Bionovax

CENRA+ Pharma 中化製藥

SyntroMed

KriSan Biotech Co., Ltd

Mithra

友華集團 OEP GROUP

培力藥品 PeiLi Pharm

王子製藥股份有限公司 Prince Pharmaceutical Co., Ltd.

PBF 寶齡富錦 PANION & BF BIOTECH INC.

SLC PHARMA

Sinphar 杏輝醫藥集團 SINPHAR GROUP

生達

Sunny Pharmtech

瑞士藥廠 SWISS PHARMA

synmosa

生泰 SYN-TECH

TA FONG Pharma

TBC Taiwan Biotech Co., Ltd.

SHENG ZOU RUBBER & PLASTIC

Ubip

元宙製藥 YCP Yuanchou Pharma

YSP

YUNG ZIP CHEMICAL

Members Services List

		Bionovax	Cenra Pharma	SyntroMed	Krisan	Mithra	OEP	Pei Li	Prince	PBF	SLC	Sinphar	SCP
		Bionovax Corp.	Cenra Pharma	SyntroMed	Krisan Biotech Co., Ltd.	Mithra Biotechnology Inc.	Orient EuroPharm Co., Ltd.	Pei Li Pharmaceutical Industrial Co.,Ltd.	Prince Pharmaceutical Co., Ltd.	Panion & BF Biotech Inc.	Savior Lifetec Corporation	Sinphar Pharmaceutical Co. Ltd.	Standard Chem. & Pharm. Co., Ltd.
Dosage Forms	Sterile-Liquid		■		■		■					■	■
	Sterile-Semi-Solid				■							■	
	Sterile-Solid				■		■				■		
	Liquid		■	■						■		■	■
	Semi-Solid		■	■			■	■		■		■	■
	Solid		■	■			■	■		■		■	■
	Patches									■			
	Aerosols												
	Biologics				■								
	API	■	■		■				■	■	■	■	
	Penicillins		■										
	Cephalosporins		■										■
	Hormones							■				■	
	Cytotoxics				■							■	
	Dietary Supplement			■			■		■	■	■	■	
More	Packaging Materials											■	
	CRO Services					■						■	

Members Services List

		Sunny	Swiss	Synmosa	Syn-Tech	TF	TBC	SZ	UBIP	YCP	YSP	YZC
		Sunny Pharmtech Inc.	Swiss Pharmaceutical Co., Ltd.	Synmosa Biopharma Corporation	Syn-Tech Chem.& Pharm. Co., Ltd.	Ta Fong Pharmaceutical Co., Ltd.	Taiwan Biotech Co., Ltd.	Taiwan Tasheh Biotech Co.,Ltd.	UBI Pharma Inc.	Yuan Chou Chemical & Pharmaceutical Co., Ltd.	Yung Shin Pharm. Ind. Co., Ltd.	Yung Zip Chemical Ind. Co., LTD
Dosage Forms	Sterile-Liquid	■	■			■	■		■		■	
	Sterile-Semi-Solid											
	Sterile-Solid	■							■		■	
	Liquid	■	■	■		■	■		■	■	■	
	Semi-Solid	■	■	■		■			■	■	■	
	Solid	■	■	■		■	■		■	■	■	
	Patches						■					
	Aerosols			■			■					
	Biologics								■			
	API	■		■	■		■				■	■
	Penicillins						■				■	
	Cephalosporins		■				■				■	
	Hormones			■		■						
	Cytotoxics	■									■	
	Dietary Supplement		■	■		■	■				■	
More	Packaging Materials	■						■				
	CRO Services											

Bionovax

Bionovax Corp.
台灣諾亞生技股份有限公司

www.bionovax.com

Services

Heparin API manufacture (Heparin Sodium, Enoxaparin sodium and Heparinoid)

Therapeutic Areas

1. Anticoagulant
2. Injectables

Dosage Forms

1. Injectables
2. Solution

Introduction

BIONOVAX Corp completed the main construction of its Active Pharmaceutical Ingredient (API) manufacturing plant in March 2017 at the Longtan Science Park in Hsinchu Science Park. In 2019, the company built an API manufacturing facility compliant with PIC/S GMP standards. With its innovative manufacturing processes, the company obtained approval for the registration of domestically produced heparin sodium API in August 2023. In 2024, it was certified by the Ministry of Health and Welfare's Food and Drug Administration as Taiwan's first and only pharmaceutical plant meeting PIC/S GMP standards for heparin APIs. The facility specializes in producing high-quality heparin (Unfractionated Heparin, UFH) and low molecular weight heparin (LMWH) anticoagulant APIs.

Heparin is widely used in surgical procedures (particularly cardiovascular surgeries), dialysis patient treatments, and medical devices. It is also used as an anticoagulant during blood transfusions to prevent coagulation and in blood banks to preserve fresh blood.

With the global population aging, the prevalence of cardiovascular and cerebrovascular diseases continues to rise. Heparin Sodium is regarded as one of the most important and widely used anticoagulant and antithrombotic drugs in modern clinical practice.

Highlights of the Year

BIONOVAX Corp heparin API strictly follows ICH Q3D, comprehensively ensuring viral clearance and heavy metal removal throughout manufacturing processes safety.

CENRA+ Pharma 中化製藥

Cenra Pharma
中化製藥

www.cenra.com

Services

1. Formulation Development
2. Contract Manufacturing
3. Commercial Packaging
4. Out-Licensing

Therapeutic Areas

1. Anti-Infectives
2. Cardiovascular
3. CNS
4. Oncology
5. Immunosuppressant
6. Respiratory
7. Gastrointestinal

Dosage Forms

1. Pre-Filled Syringe
2. Lyophilization
3. Soft Mist Inhaler
4. Nano-Suspension
5. Osmotic Controlled Release Oral Delivery System (OROS)
6. Orally Disintegrating Tablet
7. Control Released System

Introduction

Founded in 1952, Cenra Pharma (Previously known as China Chemical & Pharmaceutical Co., Ltd.) is dedicated to the innovation, R&D, manufacturing, and service and quality improvement. Currently, Cenra Pharma provides more than 430 pharmaceutical products for both human and animal uses as well as healthcare products for humans. The scope of services ranges from CMO/CDMO services of pharmaceutical and healthcare products, R&D services, household products and beauty cosmetics marketing, and home care services. Since established, Cenra Pharma has a long and well reputed record of collaboration with worldwide partners in supplying products from PIC/S GMP, Japan PMDA, USFDA certified facilities. Cenra Pharma strategizes in vertical integration of its affiliates to focus on the development of APIs and generic drugs to target global markets.

We hold an exceptional R&D team with unique technology platforms in Taiwan in creating product competitive advantages for our global partners; thus broadening Cenra Pharma's collaboration opportunities and enhancing brand image internationally.

Highlights of the Year

1. Paliperidone Palmitate Long Acting Injectable
2. Rivaroxaban F.C. Tablet
3. Ezetimibe+Atorvastatin F.C. Tablet
4. Linagliptin F.C. Tablet
5. Vortioxetine F.C. Tablet
6. Dasatinib F.C. Tablet

SyntroMed

中美醫藥
SyntroMed

www.chungmei.com.tw

Services
1. CMO & CDMO Services: Comprehensive contract manufacturing and development.
2. Professional Manufacturing (OEM & ODM): Services spanning from professional production to end-user sales.
3. Supply Chain Integration: Integration of biotech medical supply and distribution chains.
4. Research & Development: Continuous R&D focusing on cutting-edge manufacturing techniques.

Therapeutic Areas
1. Over-the-Counter (OTC) Pharmaceuticals: Primary focus on general consumer healthcare products.
2. Health Food & Dietary Supplements: Development and production of nutritional products.
3. Topical & Anti-infective Treatments: Specifically localized treatments such as Benzydamine sprays and Amorolfine lacquer.

Dosage Forms
1. Oral Liquid Preparations: Including Syrup, Solution, Emulsion, and Suspension.
2. Solid Preparations: Including Lozenge, Film-coated Tablet, Capsule, Granule, Tablet, and Pellet.
3. External Liquids: Such as medicinal sprays and topical solutions.
4. Health Food Formats: Available in Tablet, Capsule, Powder, and Granule forms.
5. Semi-solid Preparations: Capabilities for specialized semi-solid dosage formats.

Introduction

Founded in 2014 by the SyntroMed (est. 1936), SyntroMed is built on the core philosophy that "medicine is morality". With over 80 years of industry expertise, we provide comprehensive CMO and CDMO services, offering end-to-end solutions from professional manufacturing (OEM & ODM) to medical supply chain integration.

Our diverse production capabilities include oral liquids (Syrup, Supensions), Solid Preparations (Tablets, Capsules, Pellets), External Liquids, and Dietary Supplement. We are committed to continuous R&D and maintain rigorous quality standards, including cGMP, PIC/S GMP, ISO 22000, and Halal certifications.

By integrating cutting-edge techniques with global research partnerships, we aim to bring high-quality "Made in Taiwan" pharmaceuticals to Asian and international markets.

Highlights of the Year

1.	Benzydamin Hydrochloride Spray	15ml / 3mg
2.	Amorolfine HCL Lacquer 3.0ml	55.74mg

KriSan Biotech Co., Ltd.

建誼生技股份有限公司

www.krisanbiotech.com

Services
1. Global CrDMO partner for ADC, PDC, XDC Payload-Linker, Peptide and Oligonucleotide, Small Molecules from IMP to commercial scale.
2. Provide end-to-end solutions covering the entire drug development process, from optimization to commercial production, ensuring a seamless experience for clients.
3. Specialize in providing customized solutions, developing unique process and analysis methods tailored to the specific needs of clients.

Therapeutic Areas
Total CrDMO Solutions for:
1. ADC (Antibody-Drug Conjugates)
2. PDC (Peptide-Drug Conjugates)
3. AOC (Antibody-Oligonucleotide Conjugates)
4. XDC Linker-Payloads
5. Complex Small Molecules (Peptides, Oligonucleotides)

Dosage Forms
1. Solution
2. Lyophilzed Powder
3. Suspension
4. Emulsion Form

Introduction

KriSan Biotech is a global CDMO since 2015. Our team brings over 20 years of expertise in pharmaceutical development and manufacturing. We provide flexible and scalable one-stop services for antibody-drug conjugates (ADC), peptide-drug conjugates (PDC), XDC, and complex small molecules such as peptides and oligonucleotides, covering the entire process from preclinical development to GMP manufacturing and commercialization.

To date, we have delivered over 170 new chemical entity products to partners worldwide.

Highlights of the Year

1. ADC (Antibody-Drug Conjugate)
2. XDC (X-Drug Conjugate)
3. PDC (Peptide-Drug Conjugate)
4. Linker-payload
5. Complex Small Molecules (Peptides, Oligoneucleotides)

Mithra Biotechnology Inc.
明生生物科技股份有限公司

www.mithracro.com

Services
1. Bioanalysis|Biologics|BA/BE|Clinical Trial
2. Regulatory strategy and CMC consulting
3. Total solutions from non-clinical stage to phase I clinical trial
4. Bioanalytical & phase I solution for biosimilar development
5. Total solutions for antibody drug conjugates development

Therapeutic Areas
1. Oncology
2. Hematology
3. Immunology/Inflammation
4. Central Nervous System
5. Rare Diseases & Advanced Modalities

Dosage Forms
1. Oral Solid Dosage Forms (IR/CR)
2. Injectable Formulations (IV/SC/IM)
3. Long-Acting & Depot Formulations
4. Transdermal & Topical Systems
5. Advanced & Specialized Modalities (ADCs/bsAb/ASO)

Introduction

Established as Taiwan's first CRO, Mithra is one of the leading laboratories in pharmaceutical analysis and clinical development support. Our OECD GLP–compliant laboratory and GMP facility—inspected by the USFDA—operate in accordance with international recognized standards, ensuring reliability and regulatory alignment across development stages.

With experience in antibody-drug conjugates (ADCs), bispecific antibodies, nucleic acid-based therapeutics, and specially formulated new chemical entities (NCEs), we contribute to development programs through pharmacokinetic (PK)-focused evaluation and scientific interpretation.

Our work centers on translating nonclinical data into rational study designs, including first-in-human dose considerations, PK/PD modeling, and bioanalytical strategy development. We also provide analytical characterization for protein therapeutics and maintain long-standing expertise in bioavailability and bioequivalence (BA/BE) studies, offering a broad scientific foundation across the development continuum.

By applying fit-for-purpose methodologies aligned with international regulatory expectations, we aim to provide dependable data and thoughtful scientific support that help sponsors advance their programs with clarity and confidence.

Highlights of the Year
1. PK studies for drug molecules with special formulation
2. Characterization for complex molecules (ADCs, bispecific Ab)
3. Biosimilarity demonstration & Phase I solution for biosimilar development
4. Early phase clinical trials
5. PK/PD modeling & FIH dose selection

Orient EuroPharm Co., Ltd.
友華生技醫藥股份有限公司

www.oepgroup.com

Design of Methydur® Sustained Release Capsules



Services
1. CMO
2. CDMO
3. R&D
4. Sales
5. Marketing

Therapeutic Areas
1. Cardiovascular
2. Pediatric psychiatry
3. Oncology
4. Respiratory
5. Rare Disease

Dosage Forms
1. Tablets
2. Capsules
3. Injectables
4. Solutions
5. Gel

Introduction

OEP Group is a global science-based company specializing in health, nutrition, pharmaceuticals, and cosmeceuticals. Established in 1982, Orient EuroPharma Co., Ltd. (OEP) has led innovation and became publicly listed on the Taipei Exchange in 2003 (stock code: 4120). To expand its capabilities, OEP founded OrientPHARMA (stock code: 4166) in 2008 and OP NanoPharma in 2014, focusing on new drug development and manufacturing.

This vertical integration enhances expertise across pharmaceutical R&D, clinical development, production, and marketing. OEP also provides comprehensive CDMO services at its US FDA and PIC/S GMP-certified facility, specializing in injectable product development, aseptic filling, lyophilization, and analytical services.

With a strong commitment to quality and innovation, OEP Group continues advancing science and healthcare globally, delivering solutions that improve health and well-being.

Highlights of the Year

Methydur SR Launch in TW market.

培力藥品 PeiLi Pharm

Pei Li Pharmaceutical Industrial Co., Ltd.

培力藥品工業股份有限公司

www.peili.com.tw

Services

1. CMO
2. CDMO
3. R&D
4. In/Out Licensing

Therapeutic Areas

1. Hormones, Obstetrics & Gynecology
2. Genitourinary
3. Metabolic Diseases
4. Gastroenterology (GI)
5. Oncology (Non-cytotoxic)

Dosage Forms

1. Tablets
2. Capsules
3. Soft Capsules
4. Ointment
5. Suppositories

Introduction

Pei Li was established in 1976, focusing on research and development of high barrier generic drugs and healthcare products. Our facility has been passed Japan PMDA and Taiwan PICs/GMP inspection. There are 7 products which have been approved in Japan. Among these products, three are hormone-related drugs and one is high potent soft capsules.

Pei Li's Specialty:

1. Specialize in developing and manufacturing soft gelatin capsule (Soft Gel) for poorly soluble compounds or highly potent active ingredients.
2. Specialize in developing and manufacturing highly potent pharmaceutical products. Meanwhile, Pei Li has a dedicated production facility for highly potent pharmaceutical products, which can prevent cross contamination between high potent products and general pharmaceutical products.

Highlights of the Year

1. Soft Gelatin-Capsules
2. Hormone Related Products

王子製藥股份有限公司 Prince Pharmaceutical Co, Ltd.

Prince Pharmaceutical Co., Ltd.

王子製藥股份有限公司

www.prince-pharm.com.tw



Services

1. CMO
2. CDMO
3. R&D

Therapeutic Areas

APIs

Dosage Forms

APIs

Introduction

Prince Pharmaceutical Co., Ltd. has been established in 1962. Now, we focus on two business scopes. One is APIs, the other one is Dietary Supplements.

With over 50-year experience, we are one of the world's leading producers of vitamin B1 derivatives active pharmaceutical ingredients, which has been successfully supplied to Taiwan, Japan and Europe etc. Not only APIs of vitamin B1 derivatives, we also developed numbers of APIs such as Ufenamate, Tulobuterol, Aldioxa, Felbinac etc., many new projects of R&D are ongoing.

Furthermore, in order to expand capacity of plant and fulfill new business, our new APIs plant which is located in Yulin started operation in 2020.

In business of Dietary Supplements, we provide professional OEM/ODM service for well-known domestic and foreign customers.

For years, Prince Pharma has always insisted on our corporate belief of "A company that improves people's health by providing the best pharmaceuticals" and treated customer satisfaction as our highest priority.

PBF 寶齡富錦
PANION & BF BIOTECH INC.

Panion & BF Biotech Inc.
寶齡富錦生技股份有限公司

www.pbf.com.tw

Services
1. CMO
2. CDMO
3. R&D

Therapeutic Areas
1. Dermatology
2. Nephrology
3. Urology

Dosage Forms
1. Tablet
2. Capsule
3. Oral Solution
4. Cream
5. Ointment
6. Gel
7. Lotion

Introduction

Panion & BF Biotech Inc. (PBF) was established in 1976.

Over 40+ years of stringent devotion to excellence, focusing upon 4 Core Product Categories : Medical Treatment , Medical Diagnostics, Medical Prevention and Delaying Aging Process.

Business scope expansion has formed 6 corporate business units : PBF Taiwan, PBF China, Innovative Medicine, Innovative Diagnostics, Innovative Cosmetics, API.

Deriving valuable experiences from New Drug (Nephoxil) development and implementing such know-how to corporate product development, production and commercialization.

Establishing a <PBF R&D Technical Evaluation Platform> which specializes in incubating products and researching ideas into global commercialization opportunities.

With New Drug (Nephoxil) experiences and PIC/S GMP standard for manufacturing and quality control.

PBF has emerged into a Global Biotech contender.

PBF introduction: https://youtu.be/Cyy_dP7aivQ

SLC PHARMA

Savior Lifetec Corporation
松瑞製藥股份有限公司

www.saviorlifetec.com.tw

Services
1. Global Licensing & Supply
2. Domestic Pharmaceutical Sales & Distribution
3. CMO
4. CDMO

Therapeutic Areas
1. Anti-infectives (Antibiotics)
2. Antibacterial (Carbapenems)
3. Critical Care
4. Hospital-based Therapeutics
5. Severe / Complicated Infections

Dosage Forms
1. Sterile Injectables
2. Powder for Injection
3. Lyophilized Powder for Injection
4. Vial Injection
5. Small Volume Parenterals (SVPs)

Introduction

Savior Lifetec Corporation (SLC) is a specialty injectable pharmaceutical company headquartered in Tainan, Taiwan. SLC operates state-of-the-art, vertically integrated facilities with capabilities covering both sterile API manufacturing and finished dosage formulations. Our manufacturing sites meet high international quality standards and have successfully passed inspections by regulatory authorities in the US and the EU. In addition, SLC has dedicated, state-of-the-art GLP-compliant R&D centers for both API and pharmaceutical research. With strong expertise in sterile crystallization and aseptic processing of sterile powders, SLC continues to build a solid foundation for product development and innovation.

Leveraging integrated manufacturing, quality systems, and technical know-how, SLC is committed to providing reliable, high-quality products and long-term partnership support to customers worldwide.

Highlights of the Year

1. Ertapenem for Injection (Sterile Bulk)
2. Meropenem for Injection 250mg, 500mg, 1g
3. Ertapenem for Injection 1g
4. Imipenem and Cilastatin 500mg/500mg
   - A key carbapenem antibiotic manufacturer in the US market
   - EU and US FDA approved facilities
   - Robust worldwide presence spanning key markets in the US, EU, China, Asia, Middle East, and Latin America

Sinphar ® 杏輝醫藥集團 SINPHAR GROUP
PIC/S GMP · ISO9001 · ISO17025 · ISO14001 · ISO22000 · OHSAS18001

Sinphar Pharmaceutical Co., Ltd.

杏輝藥品工業股份有限公司

www.sinphar.com.tw

Services

1. CMO
   (For Drugs and Supplements)
2. CDMO
   (For Drugs and Supplements)

Therapeutic Areas

1. Oncology
2. Hormone
3. Ophthalmology
4. Gastrointestinal
5. External Use

Dosage Forms

1. Tablets
2. Capsules/Soft Capsules
3. Injections
4. Solutions
5. Lyophilizate

Introduction

Sinphar Pharmaceutical is a publicly traded company and a certified PIC/s GMP, ISO9001, ISO14001, ISO17025, ISO45001, ISO22000, and Food GMP pharmaceutical company in Taiwan.

"Safety, Stability, Validity, and Convenience" are elements we constantly emphasize in our quality policy. Holding both strong R&D capability and stringent control over product quality, Sinphar has fully demonstrated trustworthy techniques and skills in food products, cosmetics, pharmaceuticals, and anti-cancer drugs in both own brands and contract manufacturing services.

Following years of development, Sinphar has gradually consolidated its R&D capabilities in cancer drugs and new drugs, allowing us to build Taiwan's first pharmaceutical R&D center that specializes in isolated, automated production of cancer injections and cytotoxic agents.

For sales distribution channel, Sinphar was also the first to establish Sinphar Counter, a shop-in-shop business model. Now there are approximately 1,300 branches, making Sinphar Counter the largest specialized pharmacy in Taiwan.

Highlights of the Year

Lyophilization products-Under Development

Standard Chem. & Pharm. Co., Ltd.

生達化學製藥股份有限公司

www.standard.com.tw

生達化學製藥股份有限公司
STANDARD CHEM. & PHARM. CO., LTD.

Services

1. CMO
2. CDMO
3. R&D

Therapeutic Areas

1. Cardiovascular
2. Digestive
3. Diabetes
4. Anti-inflammatory
5. CNS
6. Urology
7. Respiratory

Dosage Forms

Oral Solids
(IR/SR/ER/DR/OROS/ ODT/ MUPS)

Introduction

Established in 1967, Standard Chem. & Pharm. Co., Ltd (SCP) is a renowned global pharmaceutical manufacturer with a strong international presence. We have gained widespread recognition for our commitment to excellence in the industry. Guided by our corporate philosophy of "Sincerity, Honesty, Excellence, and Innovation," SCP has emerged as a leading pharmaceutical company in Taiwan.

As the flagship company of the Standard Group, SCP offers a comprehensive portfolio of generic pharmaceutical products across all major therapeutic areas. This diverse range of offerings positions us as a fully integrated company, capable of meeting diverse market demands.

At SCP, we consistently surpass quality standards, consistently exceeding expectations. Our state-of-the-art manufacturing facilities have received numerous accolades from prestigious domestic and international regulatory agencies, including **T-FDA, US-FDA, PMDA, KFDA, and TGA,** among others. These recognitions serve as a testament to our unwavering commitment to maintaining the highest quality in our products.

Furthermore, SCP takes pride in our strong focus on customer satisfaction. We constantly strive to surpass partner expectations, ensuring mutually beneficial collaborations and solidifying our position as a leader in the Taiwanese pharmaceutical industry. By partnering with SCP, clients are guaranteed success in both the Taiwanese and international markets.

With decades of expertise and an unwavering commitment to innovation and excellence, Standard Chem. & Pharm. Co., Ltd stands as a trusted partner for pharmaceutical needs, driving progress in the global healthcare industry.

Highlights of the Year

1. Brexpiprazole ODT -Pre-BE Trial-Completed
2. Cariprazine Capsule -Pre-BE Trial-Completed

Sunny Pharmtech

Sunny Pharmtech Inc.
祥翊製藥股份有限公司

www.sunnypharmtech.com

Services
1. CMO
2. CDMO

Therapeutic Areas
1. Oncology
2. Genitourinary
3. Vitamins

Dosage Forms
1. General and High Potent OSD (Capsule, Tablet and Suspension)
2. High Potent Injection (Vial/Sterile Powder Fill)
3. High Potent Softgel

Introduction

Sunny Pharmtech Inc. specializes in the development and manufacturing of niche pharmaceutical products. With a focus on oncology, immunology, and cardiovascular health, we integrate top-tier talent with expertise in drug products and APIs to deliver high-quality, cost-effective medical solutions worldwide.

Core Strengths:

1. Reliable CDMO/CMO solutions.
2. US FDA- and TFDA-certified facilities for both drug substances and finished products.
3. In-house API development coupled with GMP manufacturing.
4. Hight Potent/Cytotoxic Handling
5. Sterile API & Injectable
6. Spray Drying
7. Nano Emulsion & Nano Milling
8. Solid Dispersion
9. ER Ion-Exchange Resinate

Highlights of the Year

1. TFDA inspection for High-Potent Tablet Production Line
2. Launched High-Potent Softgel Product
3. Launched High-Potent Injection Product

瑞士藥廠 SWISS PHARMA

Swiss Pharmaceutical Co., Ltd.
瑞士藥廠股份有限公司

www.swisspharm.com.tw

Services
1. CMO
2. CDMO
3. R&D

Therapeutic Areas
1. Psychiatry and Central Nervous System
2. Metabolism System
3. Circulatory and Cardio-Vascular System
4. Anti-Infectious
5. Anti-Inflammatory and Analgesic

Dosage Forms
1. Solid Dosage Forms: (US FDA)
   • Tablets, Granules, Capsules
2. Semi-Solid Dosage Forms:
   • Ointment, Cream, Gel
3. Liquid Dosage Forms:
   • Solution, Syrup
4. Sterile Dosage Forms:
   • Injection Solution
   (Aseptic Process and Terminal Sterilization)
5. Cephalosporin Products (Dedicated Facility):
   • Powder for Injection
   • Capsules and Granules

Introduction

Swiss Pharmaceutical was established in 1966 with the mission of developing and manufacturing quality pharmaceutical generics products. Throughout the past 55 years, Swiss operates with the mindset of continuous improvement to pursuit this mission. Headquartered in Tainan City and currently has 450+ outstanding staffs and annual revenue of USD 40 million in FY2025.

Swiss has gone through several transformation. The most recent key transformation started in 2007, when we acquired a 40,000 m^2 property to build our new facility. The facility was PIC/S GMP certified in 2012 and has opened various of opportunities which eventually lead to our first US ANDA CMO project.

For next step, we will continue to sharpen our skills in both product development and manufacturing and are seeking for partners who has the same mindset to form strategic alliance.

Highlights of the Year

Pipeline:

1. Xeljanz IR/XR (Tofacitinib)
2. Latuda (Lurasidone)
3. Lixiana (Edoxaban)
4. Xcorpri (Cenobamate)
5. Valdoxan (Agomelatine)
6. Brintellix (Vortioxetine)

Synmosa Biopharma Corporation
健喬信元醫藥生技股份有限公司

www.synmosa.com.tw

Services
1. CMO
2. CDMO

Therapeutic Areas
1. Cardiovascular
2. Respiratory
3. Hormones
4. Urology
5. CNS

Dosage Forms
1. Metered-Dose inhaler (MDI)
2. Nasal Sprays
3. Oral Solid Dosage Forms (Cap, FCT, ODT, SCT, hormone tablets, granules, Effective Tablet)
4. Solution and Even Ointment

Introduction

Synmosa Biopharma Corporation, a listed company in Taiwan OTC stock market (TW.4114), was founded in 1980. We develop sustainable business ranging from **R&D, manufacturing, contract manufacturing** as well as **sales and distribution** for both **pharmaceuticals and health supplements.**

Through constant mergers and acquisitions of potential domestic candidates, we have built a series of PIC/s manufacturing plants that specialized in the **manufacturing of metered-dose inhaler (MDI), hormone preparations, nasal sprays, effervescent tablet, granules and even ointment,** shaping us into the leading pharmaceutical company in various therapeutic areas of expertise such as **cardiovascular, respiratory, hormones, urology, oncology, and CNS.** Until today, we are still continuously expanding and putting more and more efforts in developing innovative medications and brand-name drugs.

As for global business development, we show direct presence in Hong Kong, as well as Singapore, Philippines where we allocated our own competent sales and marketing team; whereas for Northeast Asia and Southeast Asia market we have a long-established and stable collaborative business relationship with local partners. We believe in improving the quality of lives of those in need with the highest standard of pharmaceutical manufacturing technology as we move towards our vision of becoming the foremost biopharmaceutical corporation in Asia.

Highlights of the Year

Dufanas

(Azelastine HCL+Fluticasone Propionate)

Compound Nasal Spray

Syn-Tech Chem. & Pharm. Co., Ltd.
生泰合成工業股份有限公司

www.syn-tech.tw

Services
1. Manufacturing APIs
2. Sales
3. Import/Export
4. CMO
5. R&D

Therapeutic Areas
1. Cardiovascular
2. Immunology
3. Metabolic Diseases
4. Psychiatry
5. Respiratory

Dosage Forms
APIs (Powder, Liquid)

Introduction

Since 1982, Syn-Tech has been started in the API production industry, earning trust from major multinational companies. Recognized by authorities like the Taiwan FDA, US FDA, PMDA Japan, EDQM Europe, Australia and others, our commitment to quality and global standards is unwavering,

Beyond quality, we prioritize health, hygiene, environmental issues, and social responsibilities through PICs GMP, ISO systems, and ESG principles. Our mission is to serve customers with dedication, ensuring safety and delivering high-quality APIs—a commitment ingrained in our nearly 40-year journey. As we evolve, Syn-Tech remains dedicated to contributing to the pharmaceutical industry's progress through ethical and sustainable practices.

Highlights of the Year

Rizatriptan benzoate

PV Stage in 2026 Q2

- Pilot sample is available

- Will register JDMF in 2026

TA FONG Pharma

Ta Fong Pharmaceutical Co.,Ltd.

大豐製藥股份有限公司

https://tfp.com.tw/

Services

1. OEM
2. ODM
3. In/Out Licensing
4. CDMO

Therapeutic Areas

1. Respiratory
2. Hormone, Vitamins
3. Genitourinary
4. External Use

Dosage Forms

1. Tablets
2. Capsules
3. Injections
4. Powder
5. Suppositories

Introduction

Ta Fong Pharmaceutical has been dedicated to quality for over 70 years since its establishment in 1952. The company strives to provide safe, effective medications to support the health of Taiwanese people. It has earned the PIC/S GMP certification in 2013 and continuously updates its facilities and equipment.

With over 200 products and a broad range of dosage forms, Ta Fong serves major medical institutions in Taiwan and exports to Hong Kong, Macau, and Southeast Asia. The company aims to expand its high-quality, Made-in-Taiwan products globally for the well-being of all.

Highlights of the Year

Testodiol Depot Injection "T.F."- Dual-Sex Hormone Injection-Commercialised already

Taiwan Biotech Co., Ltd.

Taiwan Biotech Co., Ltd.

信東生技股份有限公司

www.taiwanbiotech.com.tw

Services

1. CMO
2. CDMO
3. R&D

Therapeutic Areas

1. Ophthalmology
2. Respiratory
3. Cardiovascular
4. Central Nervous System
5. Antimicrobial Agents

Dosage Forms

1. Oral Solids
2. Injections
3. Inhalation Solution
4. Eye Drops
5. TDDS Patch

Introduction

Taiwan Biotech is a PIC/S GMP-certified pharmaceutical manufacturer in Taiwan—PMDA-inspected and ISO 13485 certified—with strong expertise in aseptic blow-fill-seal (BFS) manufacturing. Founded in 1945, we employ 1,000+ people and support global partners with high-quality generics and CMO/CDMO services.

We support customers with end-to-end capabilities across oral solid dosage forms, sterile injectables (including vials/ampoules), pre-filled syringes, auto-injectors, inhalation solutions, ophthalmic products, transdermal patches (TDDS), and topical products (creams and ointments). Our portfolio spans cardiovascular, CNS, diabetes, respiratory, and ophthalmic therapies.

In BFS, we manufacture unit-dose eye drops, contact lens care solutions, inhalation solutions, injections, oral solutions, and wound cleansing solutions. Fill volumes range from 0.2 mL to 20 mL. We've been a trusted CMO partner to leading OTC and generic companies for over 20 years.

We provide CMO/CDMO services and welcome out-licensing and in-licensing partnerships—Let's discuss how we can support your pipeline.

Highlights of the Year

Lifitegrast Ophthalmic Solution 5%, 0.2 ml

SHENG ZOU RUBBER & PLASTIC

Taiwan Tasheh Biotech Co., Ltd.

大協生化科技股份有限公司

www.shengzou.com

Services

Medical Supplies

Therapeutic Areas

Medical Supplies

Dosage Forms

1. Pharmaceutical Packing
2. Leur Lock
3. Prefilled Syringe

Introduction

With over 50 years of material science and formulation experiences, SZ has delivered numerous advanced formulations/technologies and in turn provided uncompromised quality products in pharmaceutical packaging to customers. SZ's capabilities are uniquely situated to providing customer-suited specifications designed to go above and beyond the current standards commonly adopted by the industry.

When it comes to quality, customer service, and continuous improvement, long-establish core competencies at SZ, we are proudly to be one of the leading manufactures in the industry.

Our container closure are designed to provide superior long term stability and purity of drugs contained within, ultimately ensuring safety to patients, all backed by SZ's guaranteed solutions.

Highlights of the Year

1. Silicone Free Prefilled Syringe 0.5ml, 1ml, 2.25ml, 3ml
2. Stacked Needle and Luer Lock
3. Silicone Free Dual Chamber Prefilled Syringe

UBIP

UBI Pharma Inc.

聯亞藥業股份有限公司

www.ubi-pharma.com

Services

1. CMO
2. CDMO
3. In/Out Licensing

Therapeutic Areas

All
(Except High-Potency, Cytotoxic and Sex Hormone)

Dosage Forms

1. Injectable (Vial, Ampoule, Lyophilized)
2. Semi-solid (Cream, Ointment)
3. Tablet
4. Capsule
5. Powder

Introduction

UBI Pharma Inc. (UBIP) is one of the leading pharmaceutical companies in Taiwan. UBIP specializes in developing and manufacturing high quality generics and fusion protein drugs, as well as providing contract development and manufacturing services to global clients.

Our facility is routinely inspected by TFDA, USFDA and PMDA. We are capable of manufacturing finished dosage form of Sterile (Vial, Ampoule and Lyophilized) and Non-Sterlie (Tablet, Capsule, Powder, Cream and Ointment), and have been the contract manufacturer for multiple world renowned pharmaceutical companies for more than 20 years.

UBIP is also proud of being nominated by the goverment to manufactruring controlled drugs and COVID-19 vaccines.

UBIP continues to seek global partners to provide High-Quality, Affordable, and Innovative Medicines that help patients lead healthier lives.

Highlights of the Year

1. Recombinant Human Erythropoietin-α (EPO) Injection
2. Methylnaltrexone Injection
3. Leuprolide Injection
4. Caspofungin Injection
5. Desmopressin Injection
6. Efavirenz / Lamivudine / Tenofovir Disoproxil Fumarate Tablet

元宙製藥
YCP Yuanchou Pharma

Yuanchou Pharma
元宙化學製藥股份有限公司

www.yuanchou.com.tw

日夜痰
YCP 顆粒
SUNMUK
Granules
Acetylcysteine 600mg

Services
1. CMO
2. CDMO

Therapeutic Areas
1. Antibiotics
2. Diabetes
3. External Use
4. Gastrointestinal
5. Supplements

Dosage Forms
1. Tablets
2. Capsules
3. Granules
4. Semi-Solid Dosage Forms
5. Spray

Introduction
Yuanchou Pharma (YCP) was established in 1981. Obtained PIC/S GMP certification in 2014. We focus on generic drug development and production.

Actively invest in new ingredients, new materials, new equipment, and new process to facilitate product development.

Develop new dosage forms to meet the therapeutic needs for various clinical drugs to reduce side effects and to benefit patients.

In 2025, we have sold:

260,000,000 tablets and capsules, 17 tons of sachets, 13 tons of cream and ointment, & 5,000 liters of liquid dosage.

Highlights of the Year
Sunmuk-Granules - Newly Launch

YSP

Yung Shin Pharm. Ind. Co., Ltd.
永信藥品工業股份有限公司

www.ysp.com.tw/en/service/2

Services
1. Licensing (Product/Technology)
2. Co-Development
3. Contract Services (CDMO/CMO)

Therapeutic Areas
1. Anti-infectives
2. GI
3. Musculoskeletal system
4. Antineoplastics
5. Dermatology

Dosage Forms
1. Oral
(MR tab/cap, Matrix Tablet, Multi-Layer Tablet, Orally-Disintegrating Tablet, Powder for Suspension, Syrup)
2. Injectable
(Liposomal, Lyophilized, Powder, Solution, Suspension)
3. Topical
(Cream, Gel, Ointment, Suppository)

Introduction
Yung Shin Pharma (YSP) is committed to delivering superior value by providing high-quality, affordable healthcare products. Since 1952, YSP has developed, manufactured, and marketed solutions that improve lives and meet our clients' evolving needs. We drive our sustainable growth through in-house innovation, supporting a diversified product pipeline, strategic partnerships, and global collaboration within the Yung Shin Group.

With over two decades of successful US FDA and Japan PMDA inspections, we have built a reliable and comprehensive quality management system that ensures strict compliance with international GMP standards. Yung Shin provides specialized CMO/CDMO services, supported by a robust technological platform capable of handling a wide range of finished dosage forms (FDFs) as well as APIs.

Yung Shin supports partners in over 35 countries, covering markets across North America, Japan, China, and Australia, by providing high-quality products and professional regulatory and product registration services, empowering them to thrive in complex global markets.

Highlights of the Year
1. Cabazitaxel API and Injection
2. Micafungin API and Injection (lyophilized)
3. Probiotics

YUNG ZIP CHEMICAL

Yung Zip Chemical Ind. Co., Ltd.

永日化學工業股份有限公司

www.yungzip.com

Services

1. APIs
2. Excipient
3. CMO
4. CDMO
5. Specialty Chemicals

Therapeutic Areas

1. Anti-inflammatory/Analgesic
2. Anti fungal
3. CKD
4. Cardiovascular
5. Excipient

Dosage Forms

APIs

Introduction

Yung Zip is proud to be Taiwan's first GMP-certified API manufacturer and to hold the longest FDA inspection track record in the region. We provide integrated small-molecule solutions from early-stage intermediates to cGMP and commercial API supply. Our end-to-end platform implement seamless scale-up, standardized quality, and regulatory readiness across every development stage—making us a trusted partner for efficient, reliable, and sustainable drug development.

We combine deep chemical expertise with efficient-focused execution to help clients move faster, control risk, and advance towards market success with confidence. Seamless tech transfer, optimized process and cost-efficient scale-up solutions are provided.

Highlights of the Year

1. Edaravone - Commercialised
2. Daprodustat - Ready to Launch
3. Clonidine Hydrochloride - Commercialised

Contact TPA

www.tpatw.org.tw
BDD@pitdc.org.tw
+886-2-6625-1166

2026 Taiwan Pharmaceutical Alliance

Industrial Development Administration
MOEA

Medical and Pharmaceutical Industry
Technology and Development Center